JP2020532997A - 1型及び2型真性糖尿病の治療に(1)ネオ膵島の製造、及び(2)異なる臓器傷害及び疾病の治療に使用される様々な細胞型からのエクソソームの生成のための中空繊維系細胞培養技術の適応 - Google Patents
1型及び2型真性糖尿病の治療に(1)ネオ膵島の製造、及び(2)異なる臓器傷害及び疾病の治療に使用される様々な細胞型からのエクソソームの生成のための中空繊維系細胞培養技術の適応 Download PDFInfo
- Publication number
- JP2020532997A JP2020532997A JP2020514492A JP2020514492A JP2020532997A JP 2020532997 A JP2020532997 A JP 2020532997A JP 2020514492 A JP2020514492 A JP 2020514492A JP 2020514492 A JP2020514492 A JP 2020514492A JP 2020532997 A JP2020532997 A JP 2020532997A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- islets
- exosomes
- treatment
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 39
- 210000004027 cell Anatomy 0.000 title claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 17
- 201000010099 disease Diseases 0.000 title claims abstract description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 10
- 238000011282 treatment Methods 0.000 title claims description 18
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 239000012510 hollow fiber Substances 0.000 title claims description 7
- 238000004113 cell culture Methods 0.000 title description 7
- 210000000056 organ Anatomy 0.000 title description 6
- 230000006378 damage Effects 0.000 title description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title description 4
- 230000006978 adaptation Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 35
- 210000000130 stem cell Anatomy 0.000 claims abstract description 25
- 230000004663 cell proliferation Effects 0.000 claims abstract description 6
- 210000004153 islets of langerhan Anatomy 0.000 claims description 23
- 239000001963 growth medium Substances 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 208000030090 Acute Disease Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000983116 Homo sapiens Pancreatic prohormone Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 102100026844 Pancreatic prohormone Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- BTNMPGBKDVTSJY-UHFFFAOYSA-N keto-phenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036178 pleiotropy Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/10—Perfusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Sustainable Development (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
ネオ膵島(NeoIslet)(NI)が更に記載され、NIは間葉及び/又は脂肪幹細胞、及び膵島細胞を含む。
特定の例示的な実施形態を図面に関連して説明してきたが、当業者であれば、本開示の範囲は、本開示に明示的に示され説明される実施形態に限定されないことを認識し、理解するであろう。むしろ、本開示に記載される実施形態に対する多くの追加、削除、及び修正は、法的均等物を含む、具体的に特許請求されるものなど、本開示の範囲内の実施形態を製造するために行われてもよい。加えて、開示される一実施形態からの特徴は、本明細書で企図されるように、別の開示された実施形態の特徴と組み合わせることができるが、それでもなお本開示の範囲内に含まれる。
実施例
Claims (14)
- エクソソーム(細胞外ナノ小胞)を生成する方法であって、
中空繊維系細胞増殖(HFCE)システム内の間葉又は脂肪幹細胞又は膵島又は他の細胞を増殖させることと、
培養増殖間葉又は脂肪幹細胞又は他の細胞によってHFCEシステムから放出されたエクソソームを回収することと、を含む、方法。 - 前記細胞が、70〜95%コンフルエンスまで増殖される、請求項1に記載の方法。
- 前記HFCEシステムを通して灌流される培養培地を調節して、前記中空繊維の前記ルーメンへのエクソソームの放出を強化することを更に含む、請求項1に記載の方法。
- 請求項1に記載の方法によって産生されるエクソソーム。
- T1DM又はT2DM、及び関連する微小血管疾患に罹患している対象を治療する方法であって、
請求項1に記載の方法によって産生されたエクソソームを用いて前記対象を治療することと、を含む、方法。 - 前記エクソソームが、治療前に少なくとも2年間冷凍保存されている、請求項5に記載の方法。
- ネオ膵島を生成するための方法であって、
中空繊維系細胞増殖(HFCE)システムにおいて間葉系又は脂肪幹細胞及び膵島細胞を増殖させる培養と、
前記HFCEシステムからネオ膵島を収集することと、を含む、方法。 - 前記細胞が、70〜95%コンフルエンスまで増殖される、請求項7に記載の方法。
- 前記ネオ膵島が、
a)分化した膵島細胞及び間葉又は脂肪幹細胞、又は
b)再分化した膵島細胞及び間葉又は脂肪幹細胞を含む、請求項7に記載の方法。 - 前記膵島細胞及び幹細胞が、ネオ膵島中で約1:100、1:75、1:50、1:25、1:10、1:9、1:8、1:7、1:6、1:5、1:4、1:3、1:2、1:1、2:1、3:1、4:1、5:1、6:1、7:1、8:1、9:1、10:1、25:1、50:1、75:1,又は100:1の膵島細胞:幹細胞比にて存在する、請求項9に記載の方法。
- 前記収集されたネオ膵島が、ヒドロゲル中に配置される、請求項7に記載の方法。
- 前記収集されたネオ膵島が封入される、請求項7に記載の方法。
- T1DM又はT2DM、及び関連する微小血管疾患に罹患している対象を治療する方法であって、
前記対象を、請求項7に記載の方法により産生されたネオ膵島で治療することと、を含む、方法。 - 請求項7に記載の方法によって産生されたネオ膵島。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022208535A JP2023033336A (ja) | 2017-09-11 | 2022-12-26 | 1型及び2型真性糖尿病の治療に(1)ネオ膵島の製造、及び(2)異なる臓器傷害及び疾病の治療に使用される様々な細胞型からのエクソソームの生成のための中空繊維系細胞培養技術の適応 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762556888P | 2017-09-11 | 2017-09-11 | |
US62/556,888 | 2017-09-11 | ||
PCT/US2018/049950 WO2019051225A1 (en) | 2017-09-11 | 2018-09-07 | ADAPTATION OF HOLLOW FIBER CELL CELL TECHNOLOGY FOR THE PREPARATION OF NEO-ISLANDS OR EXOSOMES FROM STEM CELLS |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022208535A Division JP2023033336A (ja) | 2017-09-11 | 2022-12-26 | 1型及び2型真性糖尿病の治療に(1)ネオ膵島の製造、及び(2)異なる臓器傷害及び疾病の治療に使用される様々な細胞型からのエクソソームの生成のための中空繊維系細胞培養技術の適応 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020532997A true JP2020532997A (ja) | 2020-11-19 |
Family
ID=65634492
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020514492A Pending JP2020532997A (ja) | 2017-09-11 | 2018-09-07 | 1型及び2型真性糖尿病の治療に(1)ネオ膵島の製造、及び(2)異なる臓器傷害及び疾病の治療に使用される様々な細胞型からのエクソソームの生成のための中空繊維系細胞培養技術の適応 |
JP2022208535A Pending JP2023033336A (ja) | 2017-09-11 | 2022-12-26 | 1型及び2型真性糖尿病の治療に(1)ネオ膵島の製造、及び(2)異なる臓器傷害及び疾病の治療に使用される様々な細胞型からのエクソソームの生成のための中空繊維系細胞培養技術の適応 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022208535A Pending JP2023033336A (ja) | 2017-09-11 | 2022-12-26 | 1型及び2型真性糖尿病の治療に(1)ネオ膵島の製造、及び(2)異なる臓器傷害及び疾病の治療に使用される様々な細胞型からのエクソソームの生成のための中空繊維系細胞培養技術の適応 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20200208115A1 (ja) |
EP (1) | EP3681288A4 (ja) |
JP (2) | JP2020532997A (ja) |
AU (1) | AU2018327318B2 (ja) |
CA (1) | CA3073762A1 (ja) |
NZ (1) | NZ763301A (ja) |
WO (1) | WO2019051225A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3135617A1 (en) * | 2019-04-08 | 2020-10-15 | Symbiocelltech, Llc | Treatment of microvascular disorders with mesenchymal stem cells and their exosomes |
CN111154648B (zh) * | 2019-12-27 | 2022-10-25 | 新乡医学院三全学院 | 一种干细胞源性外泌体培养装置 |
CN113215094A (zh) * | 2021-05-17 | 2021-08-06 | 山东大学齐鲁医院 | 逆转2型糖尿病胰岛β细胞去分化的间充质干细胞外泌体及其制备方法和应用 |
CN113832003A (zh) * | 2021-10-20 | 2021-12-24 | 上海芙普瑞生物科技有限公司 | 一种便于提取制备脂肪干细胞外泌体的设备及提取工艺 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017023689A1 (en) * | 2015-07-31 | 2017-02-09 | Zen-Bio, Inc. | Exosome compositions and use thereof for soft tissue repair |
WO2017117585A1 (en) * | 2015-12-30 | 2017-07-06 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
WO2017122095A1 (en) * | 2016-01-15 | 2017-07-20 | Orbsen Therapeutics Limited | Sdc-2 exosome compositions and methods of isolation and use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6815203B1 (en) * | 1999-06-23 | 2004-11-09 | Joslin Diabetes Center, Inc. | Methods of making pancreatic islet cells |
HUE047474T2 (hu) * | 2011-06-06 | 2020-04-28 | ReGenesys BVBA | Õssejtek expanziója üreges rostbioreaktorokban |
SG11201406620QA (en) * | 2012-04-20 | 2014-11-27 | Agency Science Tech & Res | Bioreactor unit for use in bioartificial kidney device |
JP6685327B2 (ja) * | 2015-05-05 | 2020-04-22 | カトリーケ・ユニフェルシテイト・ルーヴァンKatholieke Universiteit Leuven | 膵島移植のための改善された方法 |
-
2018
- 2018-09-07 AU AU2018327318A patent/AU2018327318B2/en active Active
- 2018-09-07 NZ NZ763301A patent/NZ763301A/en unknown
- 2018-09-07 WO PCT/US2018/049950 patent/WO2019051225A1/en unknown
- 2018-09-07 JP JP2020514492A patent/JP2020532997A/ja active Pending
- 2018-09-07 CA CA3073762A patent/CA3073762A1/en active Pending
- 2018-09-07 US US16/646,112 patent/US20200208115A1/en active Pending
- 2018-09-07 EP EP18854201.3A patent/EP3681288A4/en active Pending
-
2022
- 2022-12-26 JP JP2022208535A patent/JP2023033336A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017023689A1 (en) * | 2015-07-31 | 2017-02-09 | Zen-Bio, Inc. | Exosome compositions and use thereof for soft tissue repair |
WO2017117585A1 (en) * | 2015-12-30 | 2017-07-06 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
WO2017122095A1 (en) * | 2016-01-15 | 2017-07-20 | Orbsen Therapeutics Limited | Sdc-2 exosome compositions and methods of isolation and use |
Non-Patent Citations (3)
Title |
---|
CADWELL, JJ ET AL.: "Clinical scale production and wouond healing activity of human adipose derived mesenchymal stem cell", ABSTRACT BOOK: ISEV2017, JPN6022025415, May 2017 (2017-05-01), pages 207, ISSN: 0005178526 * |
STEM CELLS TRANSLATIONAL MEDICINE, vol. 6, no. 7, JPN6023012559, May 2017 (2017-05-01), pages 1631 - 1643, ISSN: 0005025746 * |
WHITFORD, W ET AL.: "Continuous Production of Exosomes", GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, vol. 35, no. 16, JPN6022025417, 2015, pages 1 - 2, XP055436943, ISSN: 0005178525 * |
Also Published As
Publication number | Publication date |
---|---|
EP3681288A4 (en) | 2021-05-26 |
CA3073762A1 (en) | 2019-03-14 |
JP2023033336A (ja) | 2023-03-10 |
EP3681288A1 (en) | 2020-07-22 |
NZ763301A (en) | 2024-03-22 |
AU2018327318A1 (en) | 2020-04-23 |
US20200208115A1 (en) | 2020-07-02 |
WO2019051225A1 (en) | 2019-03-14 |
AU2018327318B2 (en) | 2022-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stoltz et al. | Stem cells and regenerative medicine: myth or reality of the 21th century | |
Fan et al. | Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord | |
Salewski et al. | Transplantation of neural stem cells clonally derived from embryonic stem cells promotes recovery after murine spinal cord injury | |
Toma et al. | Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart | |
Burdon et al. | Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential | |
JP5450072B2 (ja) | 組織修復および再生における腎臓由来細胞およびその使用方法 | |
JP2020532997A (ja) | 1型及び2型真性糖尿病の治療に(1)ネオ膵島の製造、及び(2)異なる臓器傷害及び疾病の治療に使用される様々な細胞型からのエクソソームの生成のための中空繊維系細胞培養技術の適応 | |
EP3124600B1 (en) | Method for generating a cell condensate for self-organisation | |
Cho et al. | Aligned brain extracellular matrix promotes differentiation and myelination of human-induced pluripotent stem cell-derived oligodendrocytes | |
US20060247195A1 (en) | Method of altering cell properties by administering rna | |
US20070054397A1 (en) | Adult cardiac uncommitted progenitor cells | |
JP2010246434A (ja) | 骨髄間質細胞及び間葉系幹細胞の培養方法、中枢神経系疾患治療用の移植細胞の製造方法 | |
US20230348860A1 (en) | Systems and methods for producing injectable enhanced stem cell exosomes, improved exosomes and methods of use | |
CN105264065A (zh) | 通过将干细胞移植到胆管壁来治疗胰腺和肝脏病症的方法 | |
Lorenzini et al. | Stem cells for end stage liver disease: how far have we got? | |
Citro et al. | Can we Re-engineer the endocrine pancreas? | |
JP5893562B2 (ja) | 乳動脈由来細胞並びに組織修復及び再生における使用方法 | |
JP6235795B2 (ja) | 細胞のリプログラミングのための組成物 | |
TWI263784B (en) | Encapsulated cell indicator system | |
Chi et al. | Cellular reprogramming of fibroblasts in heart regeneration | |
CN112004922A (zh) | 生物移植用细胞片及其制造方法 | |
Codina et al. | Current status of stem cell therapy in heart failure | |
WO2021201286A1 (ja) | ハイポテンシャル多能性幹細胞 | |
KR101828696B1 (ko) | 인슐린분비세포 이식용 조성물 및 이의 제조방법 | |
Fierabracci | Recents patents for isolating, delivering and tracking adult stem cells in regenerative medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220627 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220630 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220927 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230403 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230703 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231023 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240322 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240415 |